Employees: 4,200
Size Evolent Health (EVH) is a United States Health Care company (Miscellaneous Commercial Services) with a market value of $445M, the 2758th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.93 on 18 Nov 2026.
Performance Over six months the shares gained 1.8%, against -23.1% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 8 in its peer set.
Growth Revenue grew 14.1% over the last twelve months (peer median +0.8%); the operating margin is -1.3% (peer median -115.5%).
Valuation It trades at 9.2× forward earnings.
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.1 points below its cost of capital (7.0% WACC).
Backlog Backlog (remaining performance obligations) was $6.00M at 30 Sep 2026, down 80% on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Credit Evolent Health has 1 bond outstanding ($167M).
Short interest Short interest is 9.4% of the free float (30 Oct 2026).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.34B | $1.88B | $2.55B | $1.96B | $1.35B |
| Revenue growth | — | -27% | +30% | +45% | — |
| Gross profit | $240M | $284M | $248M | $337M | $246M |
| EBITDA | $81.1M | $111M | $126M | $154M | $95.3M |
| Net income | -$508M | -$535M | -$61.6M | -$113M | -$18.7M |
| Free cash flow | $36.7M | $4.75M | -$6.13M | $114M | -$49.9M |
| Capital expenditure | $28.2M | $34.1M | $24.9M | $28.7M | $47.5M |
| Total debt | $973M | $990M | $904M | $823M | $476M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | EVH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -19.3% | +0.2% | lowest of 8 |
| 6-month return | +1.8% | -23.1% | 4th highest of 8 |
| Distance from 52-week high | -37.2% | -46.8% | 4th highest of 8 |
| Revenue growth (TTM) | +14.1% | +0.8% | 2nd highest of 5 |
| Operating margin | -1.3% | -115.5% | 2nd highest of 6 |
| Forward P/E | 9.2× | n/a | — |
| Growth the price implies (Req g, 7 yrs) | 14.0% | n/a | — |
| Growth delivered (Del g) | +15.2% | n/a | — |
| Hurdle (Req g minus delivered) | -1.2 pp | n/a | — |
| ROIC minus cost of capital | -9.1 pp | -18.0 pp | 2nd highest of 4 |
| Net debt / EBITDA | 10.1× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Evolent Health EVH | United States | $445M | +2% | +14% | -1% | 9.2× | 14.0% | +15.2% |
| Oculis OCS | United States | $456M | -74% | n/a | n/a | n/a | n/a | n/a |
| Tectonic Therapeutic TECX | United States | $420M | -27% | n/a | n/a | n/a | n/a | n/a |
| Evotec EVT.DE | Germany | $532M | -46% | -5% | -15% | n/a | n/a | n/a |
| Adlai Nortye Ltd. Sponsored ADR ANL | United States | $610M | -23% | n/a | -134% | n/a | n/a | n/a |
| SBC Medical SBC | United States | $645M | +94% | +7% | 40% | 11.7× | -15.7% | +6.7% |
| OmniAb OABI | United States | $741M | +97% | +91% | -116% | n/a | 60.6% | -31.9% |
| Silence Therapeutics PLC Sponsored ADR SLN | United States | $1.23B | +244% | -98% | -11,920% | n/a | n/a | n/a |
Evolent Health has 1 bond outstanding with $167M face value.
Evolent Health reported $6.00M of remaining performance obligations at 30 Sep 2026, down 80% from a year earlier and down 42% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.99.